# 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

> **NCT00761735** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 94 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00761735
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761735, "5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00761735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*